<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): DECEMBER 12, 2000
ARONEX PHARMACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 0-20111 76-0196535
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION)
</TABLE>
8707 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TEXAS 77381-1191
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)
(281) 367-1666
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)
<PAGE> 2
ITEM 5. OTHER EVENTS
On December 18, 2000, Aronex Pharmaceuticals, Inc. (the "Company")
publicly disseminated a press release announcing that the Company had entered
into a license agreement with Sumitomo Pharmaceuticals Co., Ltd. ("Sumitomo") in
settlement of Sumitomo's litigation with Aronex as previously disclosed in the
Company's reports filed with the Securities and Exchange Commission under the
Securities Exchange Act of 1934, as amended.
The foregoing description is qualified in its entirety by reference to
the following documents, each of which is incorporated herein by reference: (i)
the License Agreement, dated as of December 12, 2000, by and between the Company
and Sumitomo, a copy of which is attached hereto as Exhibit 10.1, and (ii) the
Company's press release dated December 18, 2000, a copy of which is attached
hereto as Exhibit 99.1.
ITEM 7. EXHIBITS
+ Exhibit 10.1 -- License Agreement, dated as of December 12, 2000, by
and between the Company and Sumitomo Pharmaceuticals
Co., Ltd.
Exhibit 99.1 -- The Company's Press Release dated December 18, 2000.
+ Confidential treatment has been requested for portions of the
referenced agreement. The copy filed as an exhibit omits the
information subject to the confidentiality request.
-2-
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ARONEX PHARMACEUTICALS, INC.
Date: December 19, 2000
By: /s/ Terance A. Murnane
--------------------------
Terance A. Murnane
Controller
-3-
<PAGE> 4
EXHIBIT INDEX
EXHIBIT
INDEX DESCRIPTION
----- -----------
+10.1 -- License Agreement, dated as of December 12, 2000, by and between the
Company and Sumitomo Pharmaceuticals Co., Ltd.
99.1 -- The Company's Press Release dated December 18, 2000.
+ Confidential treatment has been requested for portions of the
referenced agreement. The copy filed as an exhibit omits the
information subject to the confidentiality request.
